MPMao Pang

Mao Pang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mao Pang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Liu

    Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China

    13 shared publications
  • Limin Rong

    Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China

    11 shared publications
  • Senyu Yao

    Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    5 shared publications
  • Daoqiang Huang

    Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    3 shared publications
  • Hong Li

    Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    3 shared publications
  • Jiale He

    Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Spine Endoscopic Atlas-Tissue: multi-class anatomical segmentation in endoscopic spine surgery

    by Yanhong Chen, Jianjin Zhang, Shan Wang, Qingxi Zhou, Xingyu Li, Jiapeng Li, Tianye Luo, Chaobo Feng, Zhouyang Hu, Jax Luo, et al.

    Spine Endoscopic Atlas–Tissue (SEA-T) is a multicenter dataset for pixel-level multi-class semantic segmentation in endoscopic spine surgery. It contains 3,310 expert-annotated frames from 65 patients (1,663 cervical frames from 39 patients; 1,647 lumbar frames from 26 patients) across three centers, plus 11,155 unlabeled frames. Annotations cover nine classes—upper/lower lamina, ligamentum flavum, dural sac, nerve root, adipose tissue, muscle, disc material, and instrument channel—created in 3D Slicer under multi-stage quality control, with Fleiss’ kappa of 0.789. The annotated data are split by center, procedure, and anatomy into Center A training, internal validation, internal test, and held-out sub-cohorts, with Center B and Center C external tests; unlabeled frames are kept separate. Baselines spanning convolutional and foundation-model paradigms—nnU-Net v2, CaraNet, MedSAM2, and the SAM-based MA-SAM baseline—report Dice-based evaluation and reveal center-dependent domain shift. SEA-T is released with native-resolution PNG images, NRRD/MRML masks, RGB overlay images for annotation review, and metadata.

  • Open Access

    Fibroblast activation protein and Periostin in cerebrospinal fluid: Candidate biomarkers in chronic spinal cord injury

    by Senyu Yao, Jun Kang, Xiaomin Ye, Ziqi Xie, Yaobang Lin, Xu Huang, Yangfan Yu, Jimin Guan, Zifeng Liu, Bin Liu, et al.

    Chronic spinal cord injury is biologically heterogeneous, and biomarkers that distinguish injury severity from longitudinal biological response are lacking. We evaluated whether fibroblast activation protein and Periostin in cerebrospinal fluid provide complementary, chronicity-dependent information on neurological severity and recovery in chronic traumatic spinal cord injury. This secondary biomarker study analyzed prospectively collected data and cerebrospinal fluid samples from two clinical trials. Seventy-two participants treated with human umbilical cord-derived mesenchymal stromal cells were classified as early chronic (2–12 months after injury; n = 35) or late chronic (> 12 months; n = 37); 18 early chronic participants received saline, and 14 non-spinal cord injury patients served as controls. Fibroblast activation protein and Periostin were measured before intervention and at month 3, with paired samples available for 62 human umbilical cord-derived mesenchymal stromal cell-treated participants. American Spinal Injury Association Impairment Scale (AIS) grade and motor, sensory, and mobility outcomes were assessed through month 15. At baseline, both biomarkers were inversely associated with AIS grade in the human umbilical cord-derived mesenchymal stromal cell cohort, with a stronger correlation for fibroblast activation protein ( ρ = .0.5730, P < 0.001) than Periostin ( ρ = .0.3125, P = 0.0075). Fibroblast activation protein discriminated AIS A from AIS B–D with an area under the curve (AUC) of 0.8522 and AIS A–B from AIS C–D with an AUC of 0.7337; corresponding AUCs for Periostin were 0.7009 and 0.6144. Associations with 15-month AIS outcomes were broader in early than late chronic spinal cord injury. In the early chronic human umbilical cord-derived mesenchymal stromal cell cohort, baseline fibroblast activation protein separated motor, pinprick, and light-touch improvement groups (AUCs, 0.7454–0.7989), and lower baseline fibroblast activation protein was associated with a higher cumulative probability of first AIS-grade improvement (log-rank P = 0.045). Early 3-month biomarker changes were not associated with motor improvement. In late chronic spinal cord injury, larger decreases in fibroblast activation protein and Periostin were associated with greater motor improvement ( P = 0.0218 and P = 0.0139), differentiated longitudinal motor, sensory, and mobility trajectories, and were associated with a higher cumulative probability of first AIS-grade improvement (both log-rank P = 0.035). Saline-cohort findings were heterogeneous and exploratory. Fibroblast activation protein and Periostin in cerebrospinal fluid showed complementary patterns across trial-defined chronicity strata in chronic spinal cord injury. Baseline fibroblast activation protein was consistently associated with injury severity and subsequent neurological status, particularly in early chronic spinal cord injury, whereas within-person changes in fibroblast activation protein and Periostin after human umbilical cord-derived mesenchymal stromal cell treatment were associated with recovery in late chronic spinal cord injury and may represent candidate response-monitoring signals. These roles require independent validation, and the treatment specificity of the dynamic biomarker changes remains to be established.

  • PLIN2-PGAM5-regulated lipid droplet-mitochondria contacts drive microglial neuroinflammation after spinal cord injury via fatty acid metabolic reprogramming

    by Daoqiang Huang, Hong Li, Yiqian Luo, Pan Jiang, Haojie Zhang, Dingzhong Cheng, Longyou Xiao, Kuileung Tong, Jiale He, Zengbo Lu, et al.


  • Open Access

    Clinical trial landscape of cell therapy for spinal cord injury: from integrated practices to future developments

    by Jun Kang, Senyu Yao, Songfu Zou, Yangfan Yu, Xu Huang, Ziqi Xie, Yaobang Lin, Bin Liu, Mao Pang, Limin Rong

    Introduction: Spinal cord injury (SCI) precipitates a multiphasic secondary injury cascade that establishes a hostile, inhibitory microenvironment, rendering the condition refractory to conventional surgical stabilization and rehabilitation. While cell-based therapies offer promise for neural reconstruction, their clinical translation is impeded by protocol heterogeneity and fragmented safety data. To address this, we mapped clinical trials for SCI to quantify patient demographic parameters, identify lineage-specific adverse-event patterns, evaluate objective motor and sensory efficacy outcomes, and analyze methodological trial designs to formulate concrete structural recommendations for future advanced-phase trials. Methods: We analyzed clinical trials from the Web of Science Core Collection (SCIE and ESCI) published since 2005. The dataset comprised 116 eligible studies involving patients with SCI receiving cellular therapies with reported safety outcomes. We employed a dual-method approach combining manual extraction of clinical characteristics (demographics, interventions, adverse events, efficacy outcomes) with quantitative data analysis. Statistical associations between therapeutic variables (cell type, route, dosage) and safety profiles were evaluated using Fisher’s exact test. Results: The clinical landscape is predominantly defined by early-phase (Phase 1: 59.5%), single-arm investigations (63.8%) utilizing autologous bone marrow-derived cells. Reflecting a cautious paradigm to minimize severe complications, patient selection frequently targeted the hemodynamically stable chronic phase (58.3%) and thoracic SCI (21.6%). Safety analyses revealed lineage-specific profiles: mesenchymal stromal cells were significantly associated with transient fever ( P = 0.038), whereas intrathecal administration correlated with procedural symptoms such as headache ( P < 0.001). The observation of higher systemic adverse event rates in low-dose cohorts was likely confounded by the mandatory concurrent immunosuppressive regimens required for specific allogeneic lineages, rather than the absolute cell dose. Regarding therapeutic efficacy, outcomes were critically influenced by the chronological phase of injury. Patients treated in the acute or subacute phases exhibited higher rates of neurological improvement, though distinguishing this from spontaneous recovery remains challenging, whereas chronic phase interventions demonstrated more limited primary sensorimotor gains. Additionally, intrathecal administration showed an advantage in preserving sensory pathways due to minimized structural disruption, while dose requirements could not be generalized and varied fundamentally based on specific cellular mechanisms of action. Discussion: While the baseline safety of cellular transplantation for spinal cord injury is established, clinical translation remains hindered by methodological heterogeneity, imprecise patient stratification, and a reliance on single-arm trial designs. To navigate this translational bottleneck, future investigations should adopt multi-tiered methodological frameworks. First, study designs should transition toward controlled protocols, utilizing crossover designs for chronic cohorts and matched historical or synthetic controls for acute and subacute phases. Concurrently, patient selection must evolve from broad clinical grading to advanced stratification. Integrating biomarkers, electrophysiology, and imaging to objectively quantify tissue sparing can better identify responsive subgroups, thereby improving trial efficiency and accelerating clinical translation. Beyond cohort refinement, intervention parameters, specifically dosage and delivery routes, should be individualized according to cell lineage, as adverse events associate more with intrinsic cellular biology and procedural invasiveness. Furthermore, isolating the true therapeutic effect requires the standardization and reporting of confounding variables, such as immunosuppressive regimens and physical rehabilitation. Finally, by separating shorter-term efficacy measurements from long-term safety registries, the field can facilitate a more reliable and objective clinical translation.

  • Soft substrate priming erases fibrotic mechanical memory in mesenchymal stromal cells via YAP lysosomal degradation to improve therapeutic efficacy for spinal cord injury

    by Senyu Yao, Yanyan Lv, Mao Pang, Xiaofan Lai, Ziqi Xie, Yaobang Lin, Jiawei Di, Yangfan Yu, Jun Kang, Xu Huang, et al.


  • Open Access

    Dual-targeting nanoparticles enhance microglial P2Y12R expression to promote neuronal mitophagy for repairing spinal cord injury

    by Zhenming Tian, Hong Li, Yunheng Jiang, Huiye Wei, Yubao Lu, Senyu Yao, Mao Pang, Xintao Shuai, Bin Liu, Limin Rong

    Spinal cord injury (SCI) leads to severe mitochondrial dysfunction and ROS cascade, with microglia playing a dual role in both exacerbating damage and providing neuroprotection. Recent evidence has highlighted the importance of P2Y12R in microglial-neuron interactions, particularly in modulating mitochondrial quality control and mitigating oxidative stress. Here, we develop a dual-targeting nanoparticle system (P2Y-TK-Nano) to enhance P2Y12R expression in microglia and promote neuronal mitophagy, aiming to reduce mitochondrial reactive oxygen species (mtROS) and improve neuronal survival following SCI. The P2Y-TK-Nano system combines a ROS-responsive thioketal bond for injury-site targeting with an MG1 peptide to selectively target microglia. This design enables precise nanoparticle delivery to the ROS-enriched injury microenvironment, effectively restoring P2Y12R expression in microglia. Microglia treated with P2Y-TK-Nano exhibit elevated P2Y12R expression, leading to increased interaction with injured neurons, improved mitophagy, and reduced mtROS production. These combined effects significantly attenuate secondary damage and contribute to neuroprotection post-SCI. Our findings reveal a novel regulatory mechanism by which P2Y12R overexpression in microglia enhances neuronal mitophagy and mitigates oxidative stress after SCI. The dual-targeting P2Y-TK-Nano system offers a promising therapeutic approach to address microglial activation and mitochondrial dysfunction in the context of SCI.


  • Open Access

    OSBPL10 alleviates neuronal ferroptosis via lysosomal membrane repair in a PS-dependent manner after spinal cord injury

    by Haojie Zhang, Yiqian Luo, Yu Kang, Daoqiang Huang, Tianlun Zhao, Xuantao Hu, Jiawei Di, Senyu Yao, Mao Pang, Bin Liu, et al.

    Spinal cord injury (SCI) exerts severe adverse effects on patients, leading to impaired motor functions in segments remote from the injury site. Following


  • Open Access

    LXR-α/SCD1-mediated Endoplasmic Reticulum-Mitochondria Crosstalk in Inhibiting Neuronal Ferroptosis after Spinal Cord Injury

    by Pan Jiang, Yiqian Luo, Daoqiang Huang, Jiale He, Hong Li, Longyou Xiao, Senyu Yao, Mao Pang, Limin Rong, Bin Liu

    Spinal cord injury (SCI) causes extensive neuronal loss, in which ferroptosis is critically involved. Although lipid transport at endoplasmic reticulum-mitochondria contact sites (ERMCSs) has been implicated in facilitating ferroptosis, the neuron-specific regulatory mechanisms remain elusive. Here, we show that neuronal ferroptosis is characterized by excessive ERMCS formation. Mechanistically, a systematic screening revealed the down-regulation of stearoyl-CoA desaturase 1 (SCD1), a critical enzyme in the synthesis of monounsaturated fatty acids (MUFAs) in neurons, following SCI (in vivo) or erastin treatment (in vitro). We demonstrated that SCD1 deficiency is the driving force behind aberrant ERMCS expansion, leading to increased lipid peroxidation and neuronal ferroptosis. Conversely, SCD1 overexpression could reverse these effects. Furthermore, we identified liver X receptor alpha (LXRα) as a direct transcriptional activator of SCD1. Pharmacological activation of LXRα with T0901317 upregulated SCD1 expression, which in turn restrained ERMCS formation, elevated MUFA levels, and ultimately inhibited neuronal ferroptosis. In murine SCI models, both adeno-associated virus-mediated neuronal SCD1 overexpression and LXRα agonist treatment effectively mitigated excessive ERMCS, reduced lesion size, preserved neuronal architecture, and improved functional recovery. Collectively, our study establishes the LXRα–SCD1 axis as a novel and druggable pathway for reducing neuronal loss and improving functional recovery by modulating ERMCS-dependent lipid exchange dynamics, revealing promising therapeutic targets after central nervous system trauma.


  • Open Access

    Global, regional, and national burden trends of spinal fractures from 1990 to 2021: a population-based study

    by Zhizhong Shang, Yubao Lu, Jiale He, Jiawei Di, Zifang Huang, Pan Zhou, Lang Mai, Ruijue Zhu, Yankui Liu, Mao Pang, et al.

    Background: Spinal fractures have become a significant cause of health loss and an increasing disease burden due to their high incidence and disability risk. However, the current understanding of the disease burden and its trend remains limited, which hinders the effectiveness of public health interventions. Methods: Data for this study were sourced from the standardized Global Burden of Disease (GBD) 2021 database. Various analytical methods, including trend analysis, correlation analysis, age-period-cohort analysis, frontier analysis, health inequality analysis, and predictive analysis, were used to explore the current status and trends of the disease burden associated with spinal fractures. Results: From 1990 to 2021, the age-standardized rate (ASR) of spinal fractures globally showed a downward trend, and this trend is expected to continue in the future. However, the absolute number of spinal fracture cases has steadily increased. Since 2018, the rate of decline in the age-standardized prevalence rate and years lived with disability has slowed. In 2021, there were 7.4975 million new cases of spinal fractures globally, with 5.3714 million existing patients, resulting in 546 000 years lived with disability. Significant disease burden inequalities were observed across different regions, with a notable increase in the burden as the Socio-Demographic Index (SDI) rises. High-SDI regions and countries faced the most severe disease burden. The ASR remained low for individuals under 60 years of age, with both the ASR and actual cases higher in males than females. For individuals aged 60 years and above, the ASR significantly increased, with females surpassing males. The ASR shows an overall decreasing trend across different genders and age groups, but the absolute inequality is greater in men than in women. Additionally, falls, other exposures to mechanical forces, and motor vehicle road injuries were the leading causes of spinal fractures. Conclusion: Although the ASR of spinal fractures has significantly decreased, the absolute number of patients continues to rise, and heterogeneity exists across countries, regions, age groups, genders, and over time. These findings highlight the need for more targeted and personalized public health interventions in the future.


  • Low back pain in aging populations: A global analysis of disability and healthcare burden over three decades

    by Shaomin Huang, Zengbo Lu, Siwei Xie, Jiale He, Yubao Lu, Mao Pang, Bin Liu

    Background: Low back pain (LBP) has emerged as a critical public health concern whose associated disability burden and healthcare expenditures have been persistently escalating among aging populations worldwide. Objective: This global study analyzed the disability burden of LBP among the older population for over three decades and identified interventions specifically targeting older adults. Methods: Repeated cross-sectional data on LBP among individuals aged ≥65 years from the Global Burden of Disease Study 2021 were extracted and compared to age-standardized rates of LBP incidence and disability adjusted life years (DALYs) across various demographic and geographic categories. Results: Countries with a high sociodemographic index (SDI), advanced health systems, and high incomes, including North America and the Latin America and Caribbean region, exhibited the highest incidence rates and DALYs of LBP. Occupational ergonomics is still the primary factor for LBP in countries with low SDI, and minimal health level countries. Body mass index (BMI) was substantially increased in all global subgroups, especially in countries with low–middle SDI, limited health systems, world bank low-income level groups. Conclusion: Advanced economic development and healthcare showed a non-linear correlation with LBP. High BMI is projected to become a predominant modifiable risk factor for LBP progression, highlighting the urgent need for the implementation of lifestyle strategies.